Michael Hoffman - Onconova Therapeutics Chairman of the Board
| ONTXDelisted Stock | USD 7.93 0.00 0.00% |
Chairman
Mr. Michael B. Hoffman serves as Chairman of the Board of Onconova Therapeutics, Inc., since 2006. He is a member of the board of directors since December 2002. Since 2003, Mr. Hoffman was a managing director of Riverstone Holdings LLC, or Riverstone, where he is principally responsible for investments in power and renewable energy. Before joining Riverstone, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group L.P., or Blackstone, where he also served on the firm principal group investment committee as well as its executive committee. Prior to joining Blackstone, Mr. Hoffman was managing director and cohead of the mergers and acquisitions department at Smith Barney, Harris Upham Co since 2006.
| Age | 66 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Phone | 267 759 3680 |
| Web | https://www.onconova.com |
Michael Hoffman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Hoffman against Onconova Therapeutics stock is an integral part of due diligence when investing in Onconova Therapeutics. Michael Hoffman insider activity provides valuable insight into whether Onconova Therapeutics is net buyers or sellers over its current business cycle. Note, Onconova Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Onconova Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Hoffman over three months ago Acquisition by Michael Hoffman of 163880 shares of Annovis BioInc subject to Rule 16b-3 | ||
Michael Hoffman over three months ago Acquisition by Michael Hoffman of 164745 shares of Annovis BioInc subject to Rule 16b-3 |
Onconova Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3807) % which means that it has lost $0.3807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.843) %, meaning that it created substantial loss on money invested by shareholders. Onconova Therapeutics' management efficiency ratios could be used to measure how well Onconova Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| Robert Kay | Ibio Inc | 84 | |
| Mark Iwicki | Pulmatrix | 51 | |
| Steven Gillis | VBI Vaccines | 62 | |
| David Dodd | GeoVax Labs | 74 | |
| Steven Rubin | VBI Vaccines | N/A | |
| Russell Plumb | Vaxart Inc | 56 | |
| David Dodd | Aeterna Zentaris | 67 | |
| Seth Lederman | Tonix Pharmaceuticals Holding | 60 | |
| Peter Nielsen | Bio Path Holdings | 66 | |
| James Bochnowski | Jaguar Animal Health | 74 | |
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 59 | |
Management Performance
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 |
Onconova Therapeutics Leadership Team
Elected by the shareholders, the Onconova Therapeutics' board of directors comprises two types of representatives: Onconova Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onconova. The board's role is to monitor Onconova Therapeutics' management team and ensure that shareholders' interests are well served. Onconova Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onconova Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henry Bienen, Director | ||
| Ramesh Kumar, Co-Founder, CEO and President and Director | ||
| Anne VanLent, Director | ||
| Ajay Bansal, CFO and Secretary | ||
| Premkumar Reddy, Founder, Lead Scientific Advisor and Director | ||
| Jerome Groopman, Director | ||
| James Marino, Independent Director | ||
| Manoj Maniar, Sr. VP of Product Devel. | ||
| Thomas McKearn, President - Research and Development | ||
| Abraham Oler, Vice President Corporate Development and General Counsel | ||
| Michael Hoffman, Chairman of the Board | ||
| Jack Stover, Director | ||
| Mark CPA, CFO COO | ||
| Victor MD, Chief Officer | ||
| Steven Fruchtman, Senior Vice President - Research and Development, Chief Medical Officer | ||
| Mark Guerin, Principal Accounting Officer and VP of Financial Planning and Accounting | ||
| Steven MD, President CEO | ||
| Mark MD, Chief Officer | ||
| Viren Mehta, Director | ||
| Adar Silverstein, Sr Devel |
Onconova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onconova Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Onconova Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Onconova Therapeutics' short interest history, or implied volatility extrapolated from Onconova Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |